Feedback / Questions
Vicineum (oportuzumab monatox) - Sesen Bio
https://www.businesswire.com/news/home/20220718005162/en/Sesen-Bio-Announces-Strategic-Decision-to-Pause-Clinical-Development-of-Vicineum%E2%84%A2-in-the-US
Jul 18, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next